Description | BL-004-500containsaproprietarymixtureofproteinsandbufferreagentsdesignedtoreduceheterophilicinteractionsinELISAassaysutilizingsheepImmunoReagents. FollowingELISAassaysintheBiosensisRapidTMELISArangehavebeenvalidatedtoachieveaccurateresultsusingBL-004-500: BEK-2217/2240,HumanproBDNF;Application:Serum,Citrate-Plasma BEK-2221,HumanNT3;Application:Plasma(CitrateandEDTA) BEK-2237,HumanproBDNF;Application:Serum,EDTA-Plasma OnevialofBL-004-500contains500µgIgGwhichissufficientassamplediluentadditiveforone96-wellplate. OtherELISAassaysthatusesheepassayantibodiesmayalsobenefitfromadditionofblockerBL-004-500,butrequireoptimizationofworkingconcentrationandassayvalidationforaccurateresults. |
Relatedproducts | BEK-2217-1P,HumanproBDNFRapidTMELISA BEK-2217-2P,HumanproBDNFRapidTMELISA BEK-2221-1P,HumanNT3RapidTMELISA BEK-2221-2P,HumanNT3RapidTMELISA BEK-2237-1P,HumanproBDNFRapidTMELISA BEK-2237-2P,HumanproBDNFRapidTMELISA BEK-2240,MatureBDNF/proBDNFComboRapidTMELISA |
BatchNo. | Seeproductlabel. |
Unitsize | 500µg |
Applications | ImmunoassayblockertoreduceoreliminateheterophilicantibodyinterferenceinsandwichELISAassaysforvalidatedsampleapplications. |
Form | Lyophilized. |
Appearance | Whitepowder. |
Reconstitution | 1)Reconstitutewith1mLassaydiluentbuffertoachieveablockerstockconcentrationof500µg/mL. 2)Dilutethisstocksolutionfurtherwith24mLassaydiluentbuffertoobtaintheblockerworkingconcentrationof20µg/mL.RefertoRapidTMELISAkitprotocolforfurtherdetails. TheworkingconcentrationofthisHAblockerneedstobeoptimizedbytheend-userforotherELISAassays. |
Storage | Storeunopenedvialat2-8°C. |
ExpiryDate | 12monthsafterpurchase(unopenedvial). |
Kitprotocol | BL-004-500_as_at_Dec2017.pdf |
Biosensis专注于神经科学领域的抗体和试剂的开发,特别是神经营养因子和神经营养因子受体。 近30年来,Biosensis一直是该领域的全球领航者和OEM供应商。除神经营养因子,我们的神经科学产品组合还被广泛用于神经退行性疾病、神经发育和神经代谢的研究。重点研究领域包括阿尔茨海默氏症(AD)、帕金森氏症(PD)和肌萎缩侧索硬化(ALS)疾病,以及自噬和代谢应激障碍,包括肥胖、代谢综合征的研究、神经免疫学和炎症。